HUTCHMED (NASDAQ:HCM) reported a net income of $456.9 million for the full year 2025, a nearly 12-fold increase from the prior year, primarily driven by a one-time divestment gain and the continued global expansion of its oncology portfolio.
The company's bottom line was significantly enhanced by a $415.8 million post-tax gain from the disposal of its stake in a non-core joint venture, Shanghai Hutchison Pharmaceuticals.
This liquidity injection, combined with profitable core operations, pushed HUTCHMED’s year-end cash balance to a robust $1.4 billion, providing a long runway for its shifting focus toward next-generation therapies.
Commercial momentum was led by FRUZAQLA® (fruquintinib), which saw ex-China in-market sales—managed by partner Takeda—surge 26% to $366.2 million.
Total in-market sales for the group reached $524.7 million.
However, consolidated revenue for the year dipped 13% to $548.5 million.
This decline was largely attributed to a 21% drop in oncology consolidated revenue to $214.4 million, impacted by lower manufacturing revenue compared to previous launch years and intensified competition for its legacy products in China, such as ELUNATE® and SULANDA®.
Despite the revenue contraction in certain segments, HUTCHMED is pivoting aggressively toward its "All with AI" and Antibody-Targeted Therapy Conjugate (ATTC) platform.
The company dosed the first patient for HMPL-A251—a first-in-class HER2-directed ATTC—in December 2025.
Management expects to initiate at least two more clinical trials for ATTC candidates in 2026, aiming to address unmet needs in solid tumors with a safer, targeted alternative to traditional chemotherapy.
Looking ahead to 2026, the company issued revenue guidance for its Oncology and Immunology segments of between $330 million and $450 million.